Assessing the Association between Biomarkers and COVID-19 Mortality Using the Joint Modelling ApproachLIFE-BASELIF3.42024-03-061OAAI
Circulating cell-free DNA and ineffective erythropoiesis in nontransfusion-dependent β-thalassemiaAMERICAN JOURNAL OF HEMATOLOGYIF9.92018-09-091OAAI
High prevalence of clinically silent HCV infection in older peopleJOURNAL OF THE AMERICAN GERIATRICS SOCIETYIF4.52015-04-277PREAI
Autoantibodies to human cytosol: a marker of sporadic porphyria cutanea tardaCLINICAL AND EXPERIMENTAL IMMUNOLOGYIF3.82008-07-078OAAI
TNF alpha polymorphisms, HFE gene mutations and acquired factors in Italian patients with porphyria cutanea tardaJOURNAL OF HEPATOLOGYIF332002-04-010PREAI
Liver cancer risk is increased in patients with porphyria cutanea tarda in comparison to matched control patients with chronic liver diseaseJOURNAL OF HEPATOLOGYIF332001-10-0160PREAI
Is hemochromatosis a risk factor for Alzheimer's disease?JOURNAL OF ALZHEIMERS DISEASEIF3.12001-09-3082PREAI
Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitisAMERICAN JOURNAL OF GASTROENTEROLOGYIF7.62001-08-01203PREAI
The hemochromatosis gene affects the age of onset of sporadic Alzheimer's diseaseNEUROBIOLOGY OF AGINGIF3.52001-07-01106OAAI
Carbohydrate-deficient transferrin, a sensitive marker of chronic alcohol abuse, is highly influenced by body ironHEPATOLOGYIF15.81999-03-0161PREAI
High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tardaHEPATOLOGYIF15.81998-01-01183OAAI
The ancestral hemochromatosis haplotype is associated with a severe phenotype expression in Italian patientsHEPATOLOGYIF15.81996-07-0168OAAI
HEPATITIS-C VIRUS AND PORPHYRIA-CUTANEA-TARDA - EVIDENCE OF A STRONG ASSOCIATIONHEPATOLOGYIF15.81992-12-01297OAAI